Retatrutide

Q: Is retatrutide more potent than tirzepatide?

Retatrutide adds glucagon receptor activity on top of GIP and GLP-1 agonism. In research models, this additional pathway contributes to distinct metabolic effects compared to dual agonists.

Q: When was retatrutide developed?

Retatrutide is a more recently developed peptide than semaglutide or tirzepatide, with preclinical data emerging in the early 2020s.

Retatrutide

Retatrutide (GIP/GLP-1/Glucagon Triple Agonist)

Research Use Only · Not for Human Consumption

Retatrutide is a next-generation synthetic peptide designed as a triple agonist at the GIP, GLP-1, and glucagon receptors. Its tri-agonist mechanism represents a more complex research model than dual agonists like tirzepatide, allowing researchers to study the combined metabolic effects of all three receptor pathways. Retatrutide is among the most recently developed research compounds in the incretin agonist category.

Key Facts

Receptor targets: GIP, GLP-1, Glucagon
Type: Triple incretin mimetic
Research stage: Advanced preclinical / clinical
Storage: -20°C lyophilized

Research Applications

Triple receptor metabolic pathway studies
Energy expenditure research
Adipogenesis and lipolysis research
Glucagon receptor role in metabolic regulation
Comparison with dual agonists in research models

Frequently Asked Questions

Is retatrutide more potent than tirzepatide?

When was retatrutide developed?

Stock Retatrutide on Your Research Compound Store

PeptiCommerce provides turn-key access to COA-documented research compounds. Your branded WooCommerce store with P2P and crypto payment support, ready in under 72 hours.

Get Started →

Key Facts

Research Applications

Frequently Asked Questions

Related Terms

Get the Research Peptide Business Playbook